dorsaVi raises $2.09M to push sensors into humanoid robotics and chips
What's the deal? dorsaViDealroom has a profile for this one. Try Dealroom →, an ASX-listed maker of FDA-cleared movement-sensor technology, has raised US$1.94M in a post-IPO equity placement backed by 62 CapitalDealroom has a profile for this one. Try Dealroom →. The Melbourne company issued 136,363,636 new shares at US$0.01 each to new and existing sophisticated, professional, and high-net-worth investors.
Why now? dorsaVi said it fielded strong demand after recent progress across its three business lines. The placement follows what the company called reinforced interest from prospective robotics and defence partners.
What's the endgame? The company wants to turn its clinical-grade human movement data — collected through wearable sensors and Video AI — into an asset for developers of humanoid robots and autonomous systems. Proceeds will expand that data library and bespoke capture capability.
Funds will also advance dorsaVi's licensed neuromorphic intellectual property and its RRAM chip development program, which targets low-power, on-device intelligence. The company is exploring applications in smart-soldier systems, aerial drones, and autonomous underwater vehicles.
One milestone: dorsaVi's first RRAM-CMOS validation chip has completed front-end and middle-of-line fabrication on TSMC's process. The wafers now move into proprietary RRAM integration, generating silicon data to guide a planned progression toward 22nm RRAM-CMOS development.
The strategy spans three connected verticals: wearable sensors and movement data; an intelligence layer built on neuromorphic IP licensed from TechnionDealroom has a profile for this one. Try Dealroom →; and semiconductors, developed with NTUDealroom has a profile for this one. Try Dealroom → and ITRIDealroom has a profile for this one. Try Dealroom →.
What could go wrong? dorsaVi was explicit that these are early-stage opportunities. The robotics and defence discussions are "areas for targeted commercial and technical exploration rather than completed integrated products," it said, with the near-term focus on defining customer requirements and converting talks into partner evaluations.
"Over the past year dorsaVi has laid the foundations," chairman Gernot Abl said, thanking shareholders and 62 Capital for its work on the raise.
The signal: dorsaVi is repositioning a decade-old clinical-sensor business toward two of the market's hottest themes — humanoid robotics and edge AI chips. Whether clinical-grade movement data and RRAM silicon become commercial products will determine if the pivot pays off.
Read more: listcorp.com
Image credit: Sangitiana
